Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix

Gynecologic Oncology

Volumn 107, Issue 2, 2007, Pages 316-319

  Bull Phelps, Shawna L ^a   Garner, Elizabeth I O ^b   Walsh, Christine S ^c   Gehrig, Paola A ^d   Miller, David S ^a   Schorge, John O ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma in situ; Cervical adenocarcinoma; Fertility sparing surgery

Indexed keywords

ADENOCARCINOMA; ARTICLE; CANCER INVASION; CARCINOMA IN SITU; ECTOPIC PREGNANCY; FEMALE; FEMALE FERTILITY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY TERMINATION; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; CARCINOMA IN SITU; COHORT STUDIES; CONIZATION; FEMALE; FERTILITY; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; HYSTERECTOMY; MEDICAL RECORDS; PARITY; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY OUTCOME; REOPERATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 35348840209     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.06.021     Document Type: Article

References (30)

1. Bray F., Carstensen B., Moller H., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev 14 (2005) 2191-2199
2. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 78 (2000) 97-105
3. Lee K.R., and Flynn C.E. Early invasive adenocarcinoma of the cervix. Cancer 89 (2000) 1048-1055
4. Wang S.S., Sherman M.E., Hildesheim A., Lacey Jr. J.V., and Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100 (2004) 1035-1044
5. Shin C.H., Schorge J.O., Lee K.R., and Sheets E.E. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol 79 (2000) 6-10
6. Andersen E.S., and Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol 86 (2002) 365-369
7. Denehy T.R., Gregori C.A., and Breen J.L. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol 90 (1997) 1-6
8. Kennedy A.W., and Biscotti C.V. Further study of the management of cervical adenocarcinoma in situ. Gynecol Oncol 86 (2002) 361-364
9. McHale M.T., Le T.D., Burger R.A., Gu M., Rutgers J.L., and Monk B.J. Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol 98 (2001) 726-731
10. Cullimore J.E., Luesley D.M., Rollason T.P., et al. A prospective study of conization of the cervix in the management of cervical intraepithelial glandular neoplasia (CIGN)-a preliminary report. Br J Obstet Gynaecol 99 (1992) 314-318
11. Muntz H.G., Bell D.A., Lage J.M., Goff B.A., Feldman S., and Rice L.W. Adenocarcinoma in situ of the uterine cervix. Obstet Gynecol 80 (1992) 935-939
12. Ostor A.G., Duncan A., Quinn M., and Rome R. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol 79 (2000) 207-210
13. Bertrand M., Lickrish G.M., and Colgan T.J. The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment. Am J Obstet Gynecol 157 (1987) 21-25
14. Widrich T., Kennedy A.W., Myers T.M., Hart W.R., and Wirth S. Adenocarcinoma in situ of the uterine cervix: management and outcome. Gynecol Oncol 61 (1996) 304-308
15. Hwang D.M., Lickrish G.M., Chapman W., and Colgan T.J. Long-term surveillance is required for all women treated for cervical adenocarcinoma in situ. J. Low. Genit. Tract Dis. 8 (2004) 125-131
16. Goldstein N.S. An investigation of the mechanisms underlying the disparity between rate of residual endocervical adenocarcinoma in situ (AIS) in hysterectomy specimens and clinical failure rate following conservatively treated AIS. Am J Clin Pathol 122 (2004) 540-545
17. Schorge J.O., Lea J.S., and Ashfaq R. Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial. J Reprod Med 48 (2003) 751-755
18. Lacour R.A., Garner E.I., Molpus K.L., Ashfaq R., and Schorge J.O. Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol 192 (2005) 1449-1451
19. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., and Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 (2006) 489-498
20. Bryson P., Stulberg R., Shepherd L., McLelland K., and Jeffrey J. Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS?. Gynecol Oncol 93 (2004) 465-468
21. Shin C.H., Schorge J.O., Lee K.R., and Sheets E.E. Cytologic and biopsy findings leading to conization in adenocarcinoma in situ of the cervix. Obstet Gynecol 100 (2002) 271-276
22. Lea J.S., Shin C.H., Sheets E.E., et al. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol 87 (2002) 129-132
23. Poynor E.A., Barakat R.R., and Hoskins WJ. Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. Gynecol Oncol 57 (1995) 158-164
24. Cohn D.E., Morrison C.D., Zanagnolo V.L., Goist M.M., and Copeland L.J. Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. Gynecol Oncol 98 (2005) 158-160
25. Kennedy A.W., elTabbakh G.H., Biscotti C.V., and Wirth S. Invasive adenocarcinoma of the cervix following LLETZ (large loop excision of the transformation zone) for adenocarcinoma in situ. Gynecol Oncol 58 (1995) 274-277
26. Krivak T.C., Retherford B., Voskuil S., Rose G.S., and Alagoz T. Recurrent invasive adenocarcinoma after hysterectomy for cervical adenocarcinoma in situ. Gynecol Oncol 77 (2000) 334-335
27. Miller B., Dunn J., Dalrymple J., and Krivak T.C. Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ. Gynecol Oncol 99 (2005) 489-492
28. Castellsague X., Diaz M., de Sanjose S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98 (2006) 303-315
29. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
30. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278